Answers are grounded in this paper and cite their sources.
This experimental study shows cholestyramine improves fecal bile acid levels in healthy dogs, indicating potential for treating BA diarrhea.
Objective To evaluate the effect of cholestyramine on the fecal dysbiosis index (DI) and the fecal excretion of conjugated and unconjugated bile acids (BAs) in dogs. Methods This was a prospective, pre-post experimental study. Individually housed research colony dogs were screened for inclusion. Included dogs were deemed healthy based on a lack of gastrointestinal signs and evaluation of annual blood work and fecal flotation. Cholestyramine was orally administered (53 to 75 mg/kg/d of active drug) to healthy dogs for 12 weeks. Dogs were maintained on the same maintenance diet for the entirety of the study. Feces were collected at 5 time points: 12 and 6 weeks prior to treatment, time 0, and 6 and 12 weeks during treatment. Repeated-measures 1-way ANOVAs were used to test differences over time for fecal conjugated and unconjugated BAs (time 0 and weeks 6 and 12 of treatment) and the fecal DI (all time points), including its individual bacterial taxa. Results 12 dogs completed the study. No adverse events following cholestyramine treatment were observed. The DI was significantly lower following cholestyramine treatment compared to before treatment and was not outside of the reference range. Cholestyramine administration significantly increased total fecal BAs, which was largely driven by a significant increase in secondary unconjugated BAs. Conclusions Cholestyramine increased the total fecal BA excretion in colony dogs and had little to no clinical effect on the DI. Clinical Relevance These findings support the investigation of the use of cholestyramine in controlled clinical trials of dogs with suspected BA diarrhea.
No takes yet. Share an insight, caveat, or question.
Tolbert et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: